Navigation Links
Clinical trial for diabetic macular edema enrolling patients
Date:3/26/2010

NEW YORK, March 26, 2010 A Phase II clinical trial for a promising treatment for diabetic eye disease has begun enrolling participants.

The Juvenile Diabetes Research Foundation, a leader in setting the agenda for diabetes research worldwide, and The Wilmer Eye Institute of Johns Hopkins University announced today that the READ 3 Study (Ranibizumab for Edema of the mAcula in Diabetes Protocol 3 with High Dose Study) will evaluate the safety and efficacy of a injections of an antibody treatment in people with diabetic macular edema (DME).

DME is a major complication of diabetes and a leading cause of blindness in adults. In DME, leakage of fluid from the blood vessels in the eye causes the retina to swell, resulting in blurring and visual loss.

The READ-3 Study is a collaboration between JDRF and Johns Hopkins University, with funding support from Genentech, Inc. (a member of the Roche group), and involves 14 clinical centers across the U.S. that will collectively enroll some 100 patients. The Wilmer Eye Institute of Johns Hopkins University will serve as the Coordinating Center for the participating clinical sites, and the Retinal Imaging Research and Reading Center at Wilmer will serve as the Reading Center for the READ 3 Study.

READ-3 is a Phase 2 study designed to compare two different doses of the antibody treatment to determine if a higher dose is more effective in improving vision and decreasing retinal thickness; it will also determine if higher doses can reduce the frequency of subsequent treatments for DME.

After screening to confirm diabetic macular edema (and no other factors that would exclude someone from the study), the participants will receive either 1 or 2 doses of ranibizumab for six months, followed by a six-month follow up-period with the option for additional treatments. Participants must be at least 18 years of age and have macular edema as the result of diabetes. For additional stud
'/>"/>

Contact: Joana Casas
mcasas@jdrf.org
212-479-7560
Juvenile Diabetes Research Foundation International
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Singapore program to provide clinical insight; showcase for regional research
2. AADR awards 2010 Neal W. Chilton Fellowship in Clinical Research to Dolphus Dawson, III
3. Cell-enriched fat grafts improve long term graft retention in preclinical study
4. GenWay Clinical Laboratory receives accreditation from College of American Pathologists
5. UAB bone center director wins distinguished service award from clinical pathology society
6. TNO and Seventh Wave sign letter of intent on joint preclinical pharmaceutical outsourcing services
7. Magnetic nanotags spot cancer in mice earlier than methods now in clinical use
8. RadMD reaches 150th clinical trial
9. New cancer drug test promises safer and more effective clinical trials
10. IRSF announces funding of first clinical trial with disease-modifying therapy for Rett syndrome
11. General tumor marker test now offered by GenWay clinical laboratory
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... Canada , April 17, 2015 ... growing security concerns, and technological advancement to drive ... until 2020   According ... Saudi Arabia Biometric Systems Market Forecast &  Opportunities, 2020 ", biometric systems ... is projected to register growth at CAGR of ...
(Date:4/14/2015)... YORK , April 14, 2015  HYPR ... IDentity Online (FIDO ® ) Alliance tm , ... specifications. FIDO members commit to share technology and ... methods that are interoperable, more secure and private, ... enable biometric identity verification that protects sensitive user ...
(Date:4/14/2015)... , April 14, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... nominated for the 2015 New York Design Awards under ... Design100, New York City Design Awards are part of ... on over 2,500 ratings from the marketplace, industry and ...
Breaking Biology News(10 mins):Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 2Saudi Arabia Biometric Systems Market to Grow at 22% Through 2020, Says TechSci Research 3HYPR Corp. Joins the FIDO Alliance 2HYPR Corp. Joins the FIDO Alliance 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3
... and instructors, Molecular Biotechnology: Principles and Applications of ... bringing it thoroughly up to date with the ... and biomedical applications. "It has been estimated ... companies employing tens of thousands of scientists. ...
... new center for the study of stem cells and to ... seven scientific initiatives announced today by NIH Director Francis S. ... the NIH Common Fund, which encourages collaborative research programs across ... that no single IC could do alone. The programs are ...
... UCLA on-campus technology incubator space at the California NanoSystems Institute, ... improve ion channel drug discovery and screening. ... a central role in generating and transmitting cardiac and neural ... out of cells; the effects of drugs that act on ...
Cached Biology News:New edition of ASM Press biotechnology text announced 2Emerging science, tech advances highlight new NIH Common Fund programs 2Emerging science, tech advances highlight new NIH Common Fund programs 3Startup joins UCLA tech incubator to develop technologies for drug discovery, screening 2
(Date:4/16/2015)... Calif. , April 16, 2015  Scientists from ... "New Drugs on the Horizon," at the American Association ... Philadelphia, PA on Sunday, April 19, 2015 ... Ph.D., Cleave,s Director of Biology, will present new in ... a first-in-class, oral inhibitor of p97, a critical enzyme ...
(Date:4/16/2015)... , April 16, 2015  EMD Serono ... KGaA, Darmstadt, Germany , appointed ... President, Head of Global Clinical Development.  Dr. Reicin ... including experience in Oncology and Immunology. She is ... having served as a Vice President in various ...
(Date:4/16/2015)... Columbia and MENLO PARK, Calif. ... Inc. (OTCQX: DMPI) (DelMar and the Company), a ... therapies in new orphan drug indications, today announced that ... added as a clinical trial site for the ongoing, ... refractory glioblastoma multiforme (GBM), the most common and deadly ...
(Date:4/16/2015)... , April 16, 2015  Northwest Biotherapeutics, Inc. ... company developing non-toxic DCVax® personalized immune therapies for ... in the Loncar Cancer Immunotherapy Index (LCINDX), a ... track the immunotherapy field within the biotechnology space.  ... "the top 25 companies" in the immunotherapy space, ...
Breaking Biology Technology:Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 2Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 3Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 2Alise Reicin Joins the Biopharmaceutical Business of Merck KGaA, Darmstadt, Germany as Head of Global Clinical Development 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 2DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 3DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 4DelMar Pharmaceuticals Adds Fourth Clinical Trial Site in Phase I/II Multicenter Study of VAL-083 for Recurrent Malignant Glioma 5NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 2NW Bio Included In New Index Of The "Top 25 Cancer Immunotherapy Companies" 3
... Feb. 21 Keryx Biopharmaceuticals,Inc. (Nasdaq: KERX ) ... at 8:30 a.m. EST to discuss the fourth quarter ... Michael S. Weiss, Chairman,and Chief Executive Officer of the ... results for this period in a press release to ...
... GOTHENBURG, Sweden, February 21 With two ... is,entering a new expansion phase. The share ... a number of significant product,launches in 2008-2009. ... with leading global pharmaceutical companies to meet ...
... 21 Human Genome,Sciences, Inc. (Nasdaq: HGSI ) ... Officer of Trevena, Inc., a privately held,drug discovery company, ... to joining Trevena, Dr. Gowen spent 15 years at ... positions in drug,discovery and development, and led the GSK ...
Cached Biology Technology:Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2007 Financial Results on Monday, February 25, at 8:30 A.M. EST 2Human Genome Sciences Appoints Maxine Gowen, Ph.D., to Its Board Of Directors 2Human Genome Sciences Appoints Maxine Gowen, Ph.D., to Its Board Of Directors 3Human Genome Sciences Appoints Maxine Gowen, Ph.D., to Its Board Of Directors 4